The International Centers for Precision Oncology Foundation (ICPO) held its second annual ICPO Theranostics Virtual Summit, themed “A New Era of Alpha Emitters and Radiopharmaceuticals,” on November 14th and 15th, 2024. Streamed live from Munich, the event attracted over 400 attendees from 37 countries. Thirty-five international experts led discussions on cutting-edge advancements in alpha emitters and radiopharmaceuticals, such as FAP, CA9, CXCR4, and GPC3, highlighting their potential to revolutionize the treatment of cancers resistant to traditional therapies. This offers new hope for improved cancer treatments worldwide.

ICPO Board of Trustees Chairman, Udo J. Vetter, opened the Summit, expressing gratitude to Summit Chairs Prof. Frederik L. Giesel and Prof. Richard P. Baum, and ICPO Foundation CEO Odile Jaume for organizing the event. He also acknowledged the contributions of the Scientific Advisory Board members: Frederik L. Giesel, Richard P. Baum, Cathy S. Cutler, Ken Herrmann, Cristina Müller, Frank Rösch, and Elcin Zan.

Moderated by Odile Jaume and Susanne Simon, the Summit featured a keynote address by Prof. Steven M. Larson on the history of alpha therapy and a presentation by Prof. Andrew M. Scott on FAP-targeted theranostics for oncology and fibrosis.

Prof. Frederik L. Giesel lauded the Summit’s success as a platform for sharing groundbreaking research and advancing clinical practice. Prof. Richard P. Baum praised the high caliber of speakers and their contributions to the field and to global cancer patient care.

Odile Jaume expressed appreciation to the speakers, sponsors, and supporters for their contributions to the event’s success and for their commitment to advancing the theranostics community.

Speakers and panelists included: Sanjana Ballal, Richard P. Baum, Hakim Bouterfa, Chris Bremer, David Cade, Dushen Chetty, Pedro Fragoso Costa, Cathy S. Cutler, Ebrahim Delpassand, Ward Digby, Marc Dweck, Germo Gericke, Jean-François Gestin, Frederik L. Giesel, Ken Herrmann, Michael Hofman, Anna Karmann, Steven M. Larson, Sze Ting Lee, Josh Mailman, Jacqueline Mock, Sherly Mosessian, Michael Nader, Jean-Pierre Pouget, Nick Pullen, Neil Quigley, Mike Sathekge, Serada Satoshi, Michael K. Schultz, Andrew M. Scott, Volker Wagner, Tadashi Watabe, Wolfgang Weber, Rudolf Werner, Elcin Zan. 

Website of the ICPO Summit 2024: ; Link to Whitepaper Summit:

About ICPO Foundation 
The International Centers for Precision Oncology Foundation (ICPO) is a non-profit organization established in 2019 to promote personalized cancer care globally. The ICPO Foundation is building an international network of diagnostic and therapeutic centers for Precision Oncology, employing a Social Franchise model based on shared knowledge, certified education through the “ICPO Academy for Theranostics,” and standardized design and processes. The Foundation aims to make Precision Oncology accessible to all patients, regardless of location or socioeconomic status. Learn more about the ICPO Foundation at and the ICPO Academy for Theranostics at

Media contact ICPO Foundation: Susanne Simon, Head of Communication & Community
Email: susanne.simon@icpo.foundation, Phone: + 49 172 8666093,

Attachments